Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H27ClN2O2 |
Molecular Weight | 398.926 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CC\C=C2\C3=C(COC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=RAAHIUIRJUOMAU-MPUCSWFWSA-N
InChI=1S/C23H27ClN2O2/c24-19-7-8-23-22(16-19)21(20-5-2-1-4-18(20)17-28-23)6-3-9-25-10-12-26(13-11-25)14-15-27/h1-2,4-8,16,27H,3,9-15,17H2/b21-6-
Molecular Formula | C23H27ClN2O2 |
Molecular Weight | 398.926 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Pinoxepin belongs to the dibenzoxepine series of drugs which are characterized by a 6-7-6 tricyclic nuclear structure. Clinical studies indicated that pinoxepin was a potent antipsychotic-sedative equally effective to chlorpromazine and thioridazine. Pinoxepin in studies with chronic schizophrenic patients displayed useful effects on behavior without unduly prominent side effects. In doses above 300 mg seizures are reported and more frequent changes in liver-function tests were noted than with standard drug, but below 300 mg pinoxepin was found to have side effects similar to chlorpromazine and marked sedative effects.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
P-5227: an active dibenzoxepine antipsychotic. | 1966 May |
|
P-5227: a 6-7-6 tricyclic antipsychotic compound. | 1966 May |
|
A PRELIMINARY STUDY OF P-5227, a new active tricyclic antipsychotic agent. | 1966 Oct |
|
Pinoxepin vs. chlorpromazine: a double-blind comparison. | 1967 Aug |
|
Effects of pinoxepin and imipramine on the mesencephalic reticular formation and amygdaloid complex in the cat: neurophysiological and clinical correlations in human subjects. | 1967 Jul |
|
Comparison of P-5227 and thioridazine in chronic schizophrenic patients. | 1967 Sep-Oct |
|
Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects. | 1969 May-Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5237376
Daily dosage: 50 mg - 1st week, 100mg - 2nd week, 150 mg - 3rd week, 200 mg - 4th week, 250 mg - 5th week, 250-400 mg - 6-10th weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:44 GMT 2023
by
admin
on
Fri Dec 15 16:02:44 GMT 2023
|
Record UNII |
Y3YKO9X8N8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09856MIG
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
2346
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110968
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
C84062
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
6436541
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
Pinoxepin
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
100000081979
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
DTXSID301136544
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
Y3YKO9X8N8
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY | |||
|
14008-66-3
Created by
admin on Fri Dec 15 16:02:44 GMT 2023 , Edited by admin on Fri Dec 15 16:02:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |